Dr. Jankovic, Director of the Parkinson's Disease Center and Movement Disorders Clinic at Baylor College of Medicine, has received research and/or training grants from Adamas, Allergan, Biotie, Civitas/Acorda, Hoffmann-La Roche, Medtronic, Merz, Neurocrine , Nuvelution, Pfizer, Prothena, Psyadon, Revance, and Teva; and has served as a consultant or as an advisory committee member for Adamas, Allergan, Merz, Prothena, Revance, and Teva.)
This article includes discussion of movement disorder emergencies, neuroleptic malignant syndrome, parkinsonism-hyperpyrexia syndrome, parkinsonism, serotonin syndrome, catatonia, dystonic storm, and Tourette syndrome. The foregoing terms may include synonyms, similar disorders, variations in usage, and abbreviations.
Movement disorders are not commonly associated with rapidly evolving life-threatening clinical syndromes; however, there are several rare syndromes that a neurologist should always consider in the differential diagnosis, such as neuroleptic malignant syndrome, parkinsonism-hyperpyrexia syndrome, acute decompensation of parkinsonism, serotonin syndrome, lethal catatonia, dystonic storm, and malignant Tourette syndrome. Prompt recognition of these syndromes and implementation of the appropriate therapy can reduce morbidity and mortality.
• Movement disorder emergencies are rare disorders, many of which have overlapping clinical features.
• Prompt recognition of the correct diagnosis and implementation of the appropriate therapy can reduce morbidity and mortality in the management of movement disorder emergencies.
• Discontinuation of the offending treatment strategy and aggressive supportive therapy is the mainstay of treatment in most movement disorder emergencies.
The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.
If you are a subscriber, please log in.
If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.